A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis

Archives of Medical Science

Volumn 6, Issue 2, 2010, Pages 236-244

  Nikfar, Shekoufeh ^a,b,c   Rahimi, Roja ^c   Rezaie, Ali ^d   Abdollahi, Mohammad ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adverse events; Efficacy; Meta analysis; Natalizumab; Relapsing multiple sclerosis; Withdrawal

Indexed keywords

GADOLINIUM; NATALIZUMAB; PLACEBO;

ANAPHYLAXIS; ARTICLE; CHOLELITHIASIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; INFECTION; META ANALYSIS; MULTIPLE SCLEROSIS; NAUSEA; PHARYNGITIS; RECURRENT DISEASE; RISK FACTOR; SERUM SICKNESS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 77951958082     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2010.13901     Document Type: Article

References (17)

1. DeAngelis T, Lublin F. Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies. Mt Sinai J Med 2008; 75: 157-167 (Pubitemid 351653974)
2. Myhr KM. Diagnosis and treatment of multiple sclerosis. Acta Neurol Scand 2008; 188: S12-21.
3. Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008; 71: 129-135
4. Engelhardt B, Kappos L. Natalizumab: targeting alpha 4-integrins in multiple sclerosis. Neurodegener Dis 2008; 5: 16-22. (Pubitemid 350261811)
5. Giovannoni G, Kinkel P, Vartanian T. Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices. Rev Neurol Dis 2007; 4: 184-193
6. Johnson KP. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis. Neurologist 2007; 13: 182-187 (Pubitemid 47057636)
7. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369-374
8. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-381 (Pubitemid 41132342)
9. Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 71: 766-773
10. Jadad A. Randomised controlled trials. London: BMJ Books; 1998.
11. Miller DH, Khan OA, Sheremata WA, et al; International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
12. O'Connor PW, Goodman A, Willmer-Hulme AJ, et al; Natalizumab Multiple Sclerosis Trial Group. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 2004; 62: 2038-2043
13. Polman CH, O'Connor PW, Havrdova E, et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
14. Tubridy N, Behan PO, Capildeo R, et al. The effect of antialpha- 4 integrin antibody on brain lesion activity in MS. Neurology 1999; 53: 466-472 (Pubitemid 29382036)
15. Sahraian MA, Radue EW. Gadolinium enhancing lesions in multiple sclerosis. IN MRI Atlas of MS Lesions. Springer; Berlin Heidelberg 2008; 45-74.
16. Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. Multiple Sclerosis Therapy Consensus Group (MSTCG). J Neurol 2008; 255: 1449-1463
17. Nikfar S, Rahimi R, Rezaie A, Abdollahi M. Efficacy and tolerability of natalizumab in relapsing multiple sclerosis; a meta-analysis. Value In Health 2009; 12: A365-6.